US Broker Ratings

Immunocore Holdings plc (IMCR)

⚠️ No article content returned.

..

Enovis Corporation (ENOV) Stock Analysis: Exploring the Healthcare Innovator’s 89.63% Potential Upside

Enovis Corporation (NYSE: ENOV), a key player in the medical devices industry, has been catching the eyes of investors with its impressive potential upside of 89.63%. As a healthcare company..

Warby Parker Inc. (WRBY) Stock Analysis: Can This Eyewear Innovator Maintain Its 15.2% Revenue Growth?

Warby Parker Inc. (NYSE: WRBY) has emerged as a significant player in the healthcare sector, specifically within the medical instruments and supplies industry. Best known for revolutionizing the eyewear market..

Tarsus Pharmaceuticals (TARS) Stock Analysis: A Promising Biotech Player with a 23% Upside Potential

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a biopharmaceutical company dedicated to eye care innovation, is garnering significant attention from investors. With a market capitalization of $3.02 billion, Tarsus operates within the..

Structure Therapeutics Inc. (GPCR) Stock Analysis: A Biotech Star with 14.83% Potential Upside

Structure Therapeutics Inc. (NASDAQ: GPCR) is drawing significant attention in the biotechnology sector, promising innovative treatments for chronic diseases while showcasing an impressive market trajectory. With a market capitalization of..

Beam Therapeutics Inc. (BEAM): Investor Outlook with a 44.78% Potential Upside

Beam Therapeutics Inc. (NASDAQ: BEAM), a Cambridge, Massachusetts-based biotechnology company, is capturing investor attention with its innovative approach to precision genetic medicines. Despite the challenges inherent in the biotech sector,..

IDEAYA Biosciences (IDYA) Stock Analysis: A Promising Upside of 38.69% in Precision Medicine

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a prominent player in the biotechnology sector, is making waves with its innovative approach to precision medicine oncology. With a market capitalization of $3.14 billion,..

Tandem Diabetes Care, Inc. (TNDM) Investor Outlook: Navigating Potential Upside in the Medical Devices Market

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) stands as a noteworthy player in the healthcare sector, specifically within the medical devices industry. With its headquarters in San Diego, California, Tandem focuses..

Mesoblast Limited (MESO) Stock Analysis: 100% Upside Potential in Biotech Breakthrough

Mesoblast Limited (MESO), an Australian biotechnology company, is capturing the attention of investors with a staggering potential upside of 100.57%. Specializing in regenerative medicine, Mesoblast is leveraging its proprietary technology..

Indivior PLC (INDV) Investor Outlook: A 35.66% Potential Upside with Strong Buy Ratings

Indivior PLC (INDV), a prominent player in the healthcare sector, is capturing significant investor attention with its robust position in the drug manufacturing industry, particularly in specialty and generic pharmaceuticals...

Clover Health Investments, Corp (CLOV) Stock Analysis: Unpacking a 27.3% Potential Upside

For investors eyeing the healthcare sector, Clover Health Investments, Corp (NASDAQ: CLOV) presents a mix of challenges and opportunities. With a market capitalization of $1.31 billion, Clover Health stands as..

AtriCure, Inc. (ATRC) Stock Analysis: A Promising 35% Upside Potential Amid Strong Buy Ratings

AtriCure, Inc. (NASDAQ: ATRC), a key player in the healthcare sector specializing in medical instruments and supplies, presents an intriguing investment opportunity for those seeking exposure to the rapidly advancing..

Travere Therapeutics, Inc. (TVTX) Stock Analysis: Strong Buy Ratings and 50% Potential Upside

Travere Therapeutics, Inc. (NASDAQ: TVTX), a biopharmaceutical company focused on rare kidney and metabolic diseases, has become a compelling point of interest for investors, showcasing a potential upside of 50.44%..

Bausch Health Companies Inc. (BHC) Stock Analysis: Exploring a 6.43% Potential Upside in a Dynamic Healthcare Landscape

Bausch Health Companies Inc. (BHC), a prominent player in the healthcare sector, operates a diversified portfolio that spans specialty pharmaceuticals and medical devices. With a market capitalization of $2.59 billion,..

Apogee Therapeutics, Inc. (APGE) Stock Analysis: A Biotech Gem with a 27.70% Upside Potential

Apogee Therapeutics, Inc. (NASDAQ: APGE), a rising star in the biotechnology sector, is captivating investor attention with its promising pipeline and a substantial upside potential of 27.70%, according to analyst..

Brookdale Senior Living Inc. (BKD) Stock Analysis: Navigating Growth in Senior Care with a 7.58% Potential Upside

Brookdale Senior Living Inc. (NYSE: BKD), a prominent player in the healthcare sector, is making waves in the medical care facilities industry with its robust portfolio of senior living communities...

CG Oncology, Inc. (CGON) Stock Analysis: A Biotech Powerhouse with 41.87% Potential Upside

CG Oncology, Inc. (CGON) is making waves in the biotechnology sector, drawing significant attention from investors with its robust pipeline of bladder cancer treatments. Headquartered in Irvine, California, this late-stage..

Schrodinger, Inc. (SDGR) Stock Analysis: Exploring a 48.90% Potential Upside in Healthcare Innovation

Schrödinger, Inc. (NASDAQ: SDGR) stands at the intersection of healthcare and technology, offering compelling prospects for individual investors. With a current market capitalization of $1.24 billion, this New York-based player..

NewAmsterdam Pharma (NAMS) Stock Analysis: Evaluating the 52.72% Potential Upside

NewAmsterdam Pharma Company N.V. (NAMS), a notable player in the biotechnology sector, has captured investor attention with its promising potential upside of 52.72%. This Dutch biopharmaceutical firm is dedicated to..

GeneDx Holdings Corp. (WGS) Stock Analysis: Navigating a 58% Potential Upside in the Genomics Space

GeneDx Holdings Corp. (NYSE: WGS) stands at the forefront of the healthcare sector’s promising genomics industry, with its specialized focus on genetic testing services. As a company with a significant..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds